TrialBMC cancer2018

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.

Yasuhiro Tsutani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.